Neuronal β-amyloid precursor protein gene expression: regulation by aurintricarboxylic acid

β-Amyloid precursor protein (β-APP) and its derivative, amyloid β-protein (β-A4), may cause death of differentiated neurons and aurintricarboxylic acid (ATA), a metabolic inhibitor, improves neuronal survival. Therefore, we studied the effect of ATA on neuronal β-APP gene expression. ATA decreased β...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1993-10, Vol.625 (2), p.244-255
Hauptverfasser: Joseph, Rajiv, Tsang, Wayne, Han, Enji, Saed, Ghassan M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:β-Amyloid precursor protein (β-APP) and its derivative, amyloid β-protein (β-A4), may cause death of differentiated neurons and aurintricarboxylic acid (ATA), a metabolic inhibitor, improves neuronal survival. Therefore, we studied the effect of ATA on neuronal β-APP gene expression. ATA decreased β-APP mRNA levels by increasing its degradation, without changing the rate of transcription. ATA decreased both steady state and interleukin-1 (IL1)-induced increase in β-APP mRNA levels. These effects of ATA were associated with rounding of cells suggestive of decreased cell adhesion or neurite retraction that was completely reversible when ATA was removed. However, β-APP mRNA levels continued to remain suppressed in neurons that were actively regrowing neurites following discontinuation of ATA. In studies carried out upto 24 h. ATA did not damage cells as determined by Trypan blue exclusion, lactate dehydrogenase (LDH)-release and transmission electron microscopy. The findings suggest that constitutive or steady state levels of β-APP mRNA may not be essential for the survival and growth of neurons and that ATA suppresses β-APP expression without causing cell damage. These observations may be a basis for studying whether ATA or a related compound could beneficially regulate β-APP levels in vivo.
ISSN:0006-8993
1872-6240
DOI:10.1016/0006-8993(93)91065-Z